In 1966, during its [[clinical development]], ethynerone was found to produce [[mammary gland]] [[tumor]]s in dogs treated with it at very high doses for prolonged periods of time.<ref name="GeilLamar2009">{{cite journal|last1=Geil|first1=R. G.|last2=Lamar|first2=J. K.|title=FDA studies of estrogen, progestogens, and estrogen/progestogen combinations in the dog and monkey|journal=Journal of Toxicology and Environmental Health|volume=3|issue=1-2|year=2009|pages=179–193|issn=0098-4108|doi=10.1080/15287397709529557}}</ref><ref name="JacobsHatfield2012">{{cite journal|last1=Jacobs|first1=A. C.|last2=Hatfield|first2=K. P.|title=History of Chronic Toxicity and Animal Carcinogenicity Studies for Pharmaceuticals|journal=Veterinary Pathology|volume=50|issue=2|year=2012|pages=324–333|issn=0300-9858|doi=10.1177/0300985812450727}}</ref><ref name="Lingeman2012">{{cite book|author=C.H. Lingeman|title=Carcinogenic Hormones|url=https://books.google.com/books?id=lOLnCAAAQBAJ&pg=PA149|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-81267-5|pages=149–}}</ref> Subsequent investigation found that [[17α-hydroxyprogesterone]] derivatves included [[anagestone acetate]], [[chlormadinone acetate]], [[medroxyprogesterone acetate]], and [[megestrol acetate]] produced similar mammary gland tumors, and that their ability to do so correlated directly with their progestogenic actions.<ref name="Lingeman2012" /><ref name="JamesPasqualini2013">{{cite book|author1=V. H. T. James|author2=J. R. Pasqualini|title=Hormonal Steroids: Proceedings of the Fifth International Congress on Hormonal Steroids|url=https://books.google.com/books?id=p1AJAwAAQBAJ&pg=PA7|date=22 October 2013|publisher=Elsevier Science|isbn=978-1-4831-5895-2|pages=7–8}}</ref> In contrast, the non-halogenated [[19-nortestosterone]] derivatives [[norgestrel]], [[norethisterone]], [[noretynodrel]], and [[etynodiol diacetate]], which are much less potent as progestogens, did not produce such effects at the dosages tested.<ref name="Lingeman2012" /> Clinical development of ethynerone was discontinued, and many of the 17α-hydroxyprogesterone derivatives were withdrawn for the indication of [[hormonal contraception]].<ref name="Lingeman2012" /><ref name="JamesPasqualini2013" /> Research later on revealed species differences between dogs and humans and established that there is no similar risk in humans.<ref name="RunnebaumRabe2012" />
